Imagin Medical Overview

i/Blue Imaging System™
Surgical Imaging

IMAGIN MEDICAL

Summary

Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive surgeries (MIS).

- Patented, ultrasensitive imaging technology based on advanced optical design and light sensors offering easy-to-use viewing options for more accurate resection
- Initial target bladder cancer; FDA process initiated; plan to launch first product commercially in late 2020 and then expand to other MIS
- Listed on the CSE under the symbol "IME" and the OTCQB under the symbol "IMEXF"

$500M U.S. Market Segment

- Bladder cancer is 6th most prevalent cancer in the U.S., 4th most prevalent in men
- Most expensive cancer to treat due to over 50% recurrence rate
- $4.0 billion spent annually on surveillance; 4 million cystoscopies annually
- 81,000 new cases per year in U.S., 380,000 worldwide

Today's Standard of Care – Significant Unmet Medical Need Remains

Endoscopes with White Light (Visible)

- 90% of the market – today's gold standard
- Highly effective if cancer protrudes above the bladder wall (Fig. A below)
- Limitations – flat tumors often appear as normal tissue; difficult to see cancer cells along the margins, contributing significantly to the greater than 50% recurrence rate (Fig. B below)

Endoscopes with White Light and Blue Filter with Fluorescing Contrast Agent

- Improves visibility of flat tumors and provides better view of the margins (Fig. C below)
- Surgical limitations - surgeon cannot operate on the blue light image:
  - White image shows the full landscape of the bladder, but does not highlight the cancer (Fig. B)
  - Blue image highlights the cancer but does not show its precise location within the bladder (Fig. C)
  - Requires the surgeon to switch back to the white image in order to perform the procedure

Endoscope with White Light

A.



White light with cancerous tumor above the organ wall

B.

Flat cancerous tumor is often not visible with traditional white light

Endoscope with Blue Filter and Fluorescence

C.



Current method using imaging agents improves cancer detection but not without limitations

Breakthrough Technology - i/Blue Imaging System

- Surpasses today's decades-old cancer detection in efficiency and accuracy by combining the improved image quality of blue light with the landscape of the white light for more precise resection of cancer
- Patented simultaneous imaging technology offers easy-to-use viewing options that display images separately or side-by-side, placing cancer in context and enables the surgeon to better visualize and resect the cancer
- Eliminates the need for the surgeon to switch back and forth between images to operate
- System agnostic - today's market limited to only one manufacturer's endoscope. i/Blue adapts seamlessly to most endoscopes on the market, dramatically expanding the market size
- Capabilities extend to other minimally invasive surgical procedures

Risk Mitigated

- Verified functional products built; pilot production scheduled for 1Q-2Q 2020
- Positive feedback from key opinion leaders at the annual American Urology Association Meeting

Opportunity Well Protected

- Exclusive license to three U.S. issued patents from Lawrence Livermore National Labs
- Additional IP being filed

Strong Management Team

- Boston-based, experienced medical device management team that has done it before
- Led by Jim Hutchens, founder of two medical device start-ups and former executive at Boston Scientific and Smith & Nephew

Strong Acquisition Environment

- Expected newsflow provides multiple potential near- and mid-term value inflection points
- Most medical device companies grow by acquisition, not organically
- Company expects to have significant value and multiple liquidity options

Contact: Jim Hutchens · jhutchens@imaginmedical.com · (617) 571-6006

CSE: IME | OTCQB: IMEXF | Frankfurt & Stuttgart Symbol: DPD2